Methscopolamine bromide is a muscarinic antagonist used to treat peptic ulcers, nausea, vomiting, and motion sickness. A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
- Mechanism
- Curator reviewed
Methscopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center). It does so by acting as a muscarinic antagonist.
- Primary indication
- Used as adjunctive therapy for the treatment of peptic ulcer.Curator reviewed · 1 structured indication
- Formula / weight
- C18H24BrNO4 · 398.297 g/mol (avg)
- First approval
- United States, 1953
- Also known as
- Hyoscine methobromide · Hyoscine methyl bromide · Methylscopolamine bromide · N-methylhyoscine bromide · N-methylscopolammonium bromide
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
CXYRUNPLKGGUJF-RAFJPFSSSA-MSMILES[Br-].[H][C@@]12O[C@]1([H])[C@H]1C[C@H](C[C@@H]2[N+]1(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1What you can answer from here — as of September 13, 2026
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Methscopolamine bromide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account